NCT05999968 2026-03-05
Abemaciclib Plus Darolutamide in Prostate Cancer That Has Spread After Initial Treatment
Eli Lilly and Company
Phase 1 Completed
Clinical Trials
16 trialsNCT04481113 2026-01-29
Abemaciclib and Niraparib Before Surgery for the Treatment of Hormone Receptor Positive HER2 Negative Breast Cancer
OHSU Knight Cancer Institute
Phase 1 Completed
NCT04627064 2025-07-25
ABEMA Alone or in COMBO With MK-6482
Dana-Farber Cancer Institute
Phase 1 Completed
NCT03099174 2025-06-24
This Study in Patients With Different Types of Cancer (Solid Tumours) Aims to Find a Safe Dose of Xentuzumab in Combination With Abemaciclib With or Without Hormonal Therapies. The Study Also Tests How Effective These Medicines Are in Patients With Lung and Breast Cancer
Boehringer Ingelheim
Phase 1 Completed
NCT02791334 2024-09-27
PACT
Eli Lilly and Company
Phase 1 Completed
NCT01394016 2024-09-19
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02644460 2023-10-26
AflacST1501
Emory University
Phase 1 Completed
NCT04514159 2023-02-01
A Study of ZN-c5 and Abemaciclib in Participants With Breast Cancer
Zeno Alpha Inc.
Phase 1 Completed
NCT02857270 2022-11-22
A Study of LY3214996 Administered Alone or in Combination With Other Agents in Participants With Advanced/Metastatic Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02688088 2022-10-18
A Study of Abemaciclib in Participants With Cancer That is Advanced or Has Spread to Another Part(s) of the Body
Eli Lilly and Company
Phase 1 Completed
NCT01655225 2022-04-08
A Study of LY3023414 in Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT04071262 2021-09-21
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Therapies in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02919696 2020-09-25
A Study of Abemaciclib (LY2835219) in Native Chinese Participants With Advanced and/or Metastatic Cancers
Eli Lilly and Company
Phase 1 Completed
NCT02079636 2020-09-11
A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC)
Eli Lilly and Company
Phase 1 Completed
NCT02014129 2020-08-24
A Study of LY2835219 in Japanese Participants With Advanced Cancer
Eli Lilly and Company
Phase 1 Completed
NCT02117648 2019-01-07
A Study of LY2835219 in Participants With Cancer
Eli Lilly and Company
Phase 1 Completed